Anti-Thomsen-nouveaupolysaccharide A1 (KT-IgM-8)

Anti-Thomsen-nouveaupolysaccharide A1 [KT-IgM-8], Recombinant, IgG1 kappa, Human
Artikelnummer
ABAAb02511-10.3-BT
Verpackungseinheit
1 mg
Hersteller
Absolute Antibody

Verfügbarkeit: wird geladen...
Preis wird geladen...
CloneID: KT-IgM-8

Heavy Chain modification: Fc Silent™

Antigen Long Description: The original antibody was generated by immunizing C57BL/6 mice against Tn-PS A1.

Buffer Composition: PBS only.

Chimeric Use Statement: This is a reformatted human IgG1 Fc Silent™ antibody, based on the original human IgM format, created for improved compatibility with existing reagents, assays and techniques.

Specificity Statement: The antibody is specific for Tn-PS A1. It does not cross react with PS A1.

Application Notes (Clone): The specificity of the original format of the antibody was confirmed by ELISA analysis. The ability of the antibody to bind cancer cells expressing the Tn antigen on the cell surface (MCF-7 and HCT-116) was evaluated by by FC. The antibody demonstrated the ability to bind both MCF-7 and HCT-116 tumor cells at 30 µg/mL with a shift in fluorescence of 49% in both cell lines. The antibody demonstrated in vitro tumor killing using an LDH assay. The assay measured that the antibody-induced complement-dependent cytotoxicity was 30%. In vivo passive immunotherapy approach using an MCF-7 cell line-derived xenograft model was evaluated. The antibody demonstrated approximately 40% reduction in tumor growth in the MCF-7 model (Trabbic et al., 2018; PMID: 30030557).
Mehr Informationen
Artikelnummer ABAAb02511-10.3-BT
Hersteller Absolute Antibody
Hersteller Artikelnummer Ab02511-10.3-BT
Verpackungseinheit 1 mg
Mengeneinheit STK
Reaktivität Human
Klonalität Recombinant
Methode ELISA, Flow Cytometry, In Vivo Assay
Isotyp IgG1 kappa
Wirt Human
Produktinformation (PDF) Download
MSDS (PDF) Download